These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32366408)

  • 21. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comparative Study of Patient-Derived Tumor Models of Pancreatic Ductal Adenocarcinoma Involving Orthotopic Implantation.
    Yanagihara K; Iino Y; Yokozaki H; Kubo T; Oda T; Kubo T; Komatsu M; Sasaki H; Ichikawa H; Kuwata T; Seyama T; Ochiai A
    Pathobiology; 2022; 89(4):222-232. PubMed ID: 35272288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.
    Logsdon CD; Arumugam T; Ramachandran V
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G283-91. PubMed ID: 26159697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.
    Pal A; Dziubinski M; Di Magliano MP; Simeone DM; Owens S; Thomas D; Peterson L; Potu H; Talpaz M; Donato NJ
    Neoplasia; 2018 Feb; 20(2):152-164. PubMed ID: 29248719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease.
    Golan T; Stossel C; Schvimer M; Atias D; Halperin S; Buzhor E; Raitses-Gurevich M; Cohen K; Pri-Chen S; Wilson J; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Yarden Y; Nataraj NB; Gallinger S; Berger R
    Oncotarget; 2017 Jun; 8(25):40778-40790. PubMed ID: 28489577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression.
    Xie T; Musteanu M; Lopez-Casas PP; Shields DJ; Olson P; Rejto PA; Hidalgo M
    PLoS One; 2015; 10(11):e0142631. PubMed ID: 26555578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer.
    Chen Q; Wei T; Wang J; Zhang Q; Li J; Zhang J; Ni L; Wang Y; Bai X; Liang T
    Pancreatology; 2020 Apr; 20(3):485-492. PubMed ID: 32113935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
    Garcia PL; Miller AL; Kreitzburg KM; Council LN; Gamblin TL; Christein JD; Heslin MJ; Arnoletti JP; Richardson JH; Chen D; Hanna CA; Cramer SL; Yang ES; Qi J; Bradner JE; Yoon KJ
    Oncogene; 2016 Feb; 35(7):833-45. PubMed ID: 25961927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.
    Zaccagnino A; Managò A; Leanza L; Gontarewitz A; Linder B; Azzolini M; Biasutto L; Zoratti M; Peruzzo R; Legler K; Trauzold A; Kalthoff H; Szabo I
    Oncotarget; 2017 Jun; 8(24):38276-38293. PubMed ID: 27542263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
    Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.
    Su HT; Weng CC; Hsiao PJ; Chen LH; Kuo TL; Chen YW; Kuo KK; Cheng KH
    Mol Cancer Res; 2013 Jul; 11(7):768-79. PubMed ID: 23552743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression.
    Hutchings D; Waters KM; Weiss MJ; Wolfgang CL; Makary MA; He J; Cameron JL; Wood LD; Hruban RH
    Am J Surg Pathol; 2018 Nov; 42(11):1556-1561. PubMed ID: 30212393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
    Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
    Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation.
    Dieter SM; Giessler KM; Kriegsmann M; Dubash TD; Möhrmann L; Schulz ER; Siegl C; Weber S; Strakerjahn H; Oberlack A; Heger U; Gao J; Hartinger EM; Oppel F; Hoffmann CM; Ha N; Brors B; Lasitschka F; Ulrich A; Strobel O; Schmidt M; von Kalle C; Schneider M; Weichert W; Ehrenberg KR; Glimm H; Ball CR
    Int J Cancer; 2017 Mar; 140(6):1356-1363. PubMed ID: 27935045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
    Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
    Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade.
    Alves F; Contag S; Missbach M; Kaspareit J; Nebendahl K; Borchers U; Heidrich B; Streich R; Hiddemann W
    Pancreas; 2001 Oct; 23(3):227-35. PubMed ID: 11590317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
    Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
    Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.